Skin stem cells, essential for continual skin regeneration and repair, have now been shown to retain a remarkably persistent memory of inflammatory events. This revelation emerged from a collaborative study led by computational biologist Dana Pe’er, PhD, and stem cell biologist Elaine Fuchs, PhD. The research dissected the chromatin accessibility landscape of skin stem cells following inflammatory stimuli, demonstrating that particular regions within the DNA maintain an “open” configuration for over a year, even as cells repeatedly divide to replenish the epidermis. This epigenetic persistence suggests that stem cells are not merely passive rebuilders but are biochemically programmed to recall prior insults and respond more rapidly upon re-exposure.

The team employed advanced machine learning models trained to recognize patterns in DNA sequences associated with long-term epigenetic alterations. Their computational approach pinpointed sequence motifs that encode the heritable nature of these chromatin states, revealing that the genome intrinsically directs methylation and chromatin dynamics across successive generations of cells. Such findings underscore a paradigm in which inflammatory memory is molecularly inscribed within the genome’s regulatory architecture, poised to influence how skin tissue adapts—or maladapts—with age and repeated environmental challenges. These insights raise compelling questions about the relationship between persistent inflammation, tissue dysfunction, and age-associated diseases, marking a new frontier in dermatological biology.

In parallel, the MSK team undertook an unprecedented genomic survey of nearly 50,000 cancer patients spanning almost 450 cancer types, leveraging data from MSK-IMPACT®, their robust tumor sequencing platform. The comprehensive analysis unveiled a striking complexity in mutation behavior contingent on the cancer context. While certain mutations act as primary oncogenic drivers in their canonical tumor types, fueling early tumor initiation and present ubiquitously across malignant cells, these very same mutations display divergent roles when found in atypical cancers. They tend to emerge later in tumor evolution, are restricted to subclonal populations, and have attenuated oncogenic functions. This nuanced understanding challenges the conventional “one mutation, one action” dogma and demands refined classification frameworks in precision oncology, tailoring therapeutic decisions to the specific genetic and cellular milieu of each tumor.

Beyond elucidating driver mutation dynamics, the extensive dataset provided fresh angles on cancer genetics, highlighting the influence of fusion genes in cancers presenting at an early age as well as revealing correlations between patients’ genetic ancestry and responsiveness to immunotherapies such as T cell receptor (TCR) treatments. The transparent availability of this enormous dataset through MSK’s cBioPortal for Cancer Genomics empowers the global research community to further dissect and harness these data to optimize personalized cancer care.

In a revealing investigation into cancer cells’ innate ability to evade immune surveillance, researchers from John Maciejowski’s lab at the Sloan Kettering Institute identified the protein BAF (barrier-to-autointegration factor) as a critical mediator in masking chromosomal instability signals. Tumors often exhibit chromosomal instability characterized by improper chromosome segregation during cell division, generating micronuclei—small extranuclear DNA bodies prone to rupture, which should alert intrinsic immune defenses. BAF functions by coating the exposed micronuclear DNA upon rupture and recruiting TREX1, an exonuclease that degrades cytosolic DNA fragments, thereby attenuating the activation of the DNA sensor cGAS and preventing the elicitation of cancer-directed immune responses.

Strikingly, depletion of BAF unleashes cGAS’s access to the micronuclear DNA, triggering a potent antitumor immune response. Furthermore, simultaneous ablation of TREX1 amplifies this effect, confirming that both components collaboratively suppress innate immune detection pathways. This discovery exposes a novel immune evasion mechanism exploited by chromosomally unstable cancers and identifies BAF as a promising therapeutic target to disrupt tumor immune camouflage, potentially enhancing responses to immunotherapies.

The final revelation from MSK concerns the epigenetic underpinnings of cellular differentiation, addressing a fundamental question in developmental biology: are enhancer elements—the genomic switches that activate gene expression programs—primed before cell fate commitment? Researchers at the Sloan Kettering Institute employed cutting-edge methodologies—including CRISPR-based chromatin interrogation, single-cell transcriptomics, and chromatin accessibility assays—to interrogate human embryonic stem cells (ESCs). Their work established that enhancers associated with fully differentiated cells are pre-marked within pluripotent ESCs well before lineage specification.

These pre-established enhancers bear distinctive molecular markers, indicating a chromatin landscape configured to anticipate future gene activation. Moreover, these “pre-enhancer” regions could autonomously initiate transcriptional programs independent of external differentiation cues. This prefiguring mechanism provides a crucial framework for understanding how pluripotent cells are epigenetically equipped to embark on diverse developmental trajectories, facilitating refined strategies for cellular reprogramming and regenerative medicine.

Co-corresponding author Julian Pulecio, PhD, emphasizes that decoding these chromatin features offers novel opportunities to model gene regulatory networks, improve the precision of in vitro differentiation protocols, and elucidate how dysregulation of enhancers contributes to disease states such as cancer. Collectively, this body of research from MSK offers transformative perspectives on the interplay between genetics, epigenetics, and cell biology, heralding a new era of personalized medicine and targeted therapies.

By interrogating the layers of genomic and epigenomic regulation across health and disease, these studies illuminate the profound intricacies of cellular memory, oncogenic heterogeneity, immune interaction, and developmental priming. They underscore how interdisciplinary approaches—combining computational biology, advanced sequencing, and molecular genetics—are key to unlocking the full potential of precision oncology and regenerative science. As these discoveries continue to ripple through the biomedical community, they promise to catalyze innovative treatments and deepen our grasp of human biology at its most fundamental levels.

Subject of Research:
Skin stem cell inflammatory memory, cancer mutation heterogeneity, cancer immune evasion mechanisms, and embryonic stem cell chromatin priming.

Article Title:
Memorial Sloan Kettering Uncovers Epigenetic Memory in Skin, Mutation Complexity in Cancer, Tumor Immune Camouflage, and Developmental Enhancer Priming

News Publication Date:
2024

Web References:
Data from MSK cBioPortal for Cancer Genomics: https://www.cbioportal.org
Articles in Science, Cancer Cell, Molecular Cell, and Cell Genomics journals (specific articles referenced in the original MSK summary)

References:
Original research studies published by teams led by Dana Pe’er, Elaine Fuchs, Chaitanya Bandlamudi, Michael Berger, John Maciejowski, Yanyang Chen, Roshan Xavier Norman, and Julian Pulecio at Memorial Sloan Kettering Cancer Center and affiliates.

Image Credits:
Memorial Sloan Kettering Cancer Center

Multiple myeloma, a malignancy of plasma cells in the bone marrow, historically has posed significant treatment challenges due to its tendency to relapse. The emergence of CAR T cell therapy, where a patient’s T cells are genetically engineered to attack myeloma cells expressing the B cell maturation antigen (BCMA), has revolutionized treatment options. Ciltacabtagene autoleucel, or cilta-cel, is among the most promising of these therapies, offering hope to patients with refractory or relapsed disease. Yet, variability remains: while some patients maintain remission for years, others experience early cancer recurrence.

The research, published in the journal Blood Advances, represents the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma patients. Employing sophisticated multi-layered analyses encompassing transcriptomics, proteomics, and immune profiling, the investigators closely monitored a cohort of 19 patients enrolled in the CARTITUDE-1 clinical trial. Blood and bone marrow samples were collected at multiple time points before and after cilta-cel infusion, allowing an unprecedented resolution of immune dynamics correlated with clinical outcomes.

Findings demonstrate that long-term remission is not solely contingent on the success of the CAR T cells infused but critically depends on the intricate interplay between these engineered cells and the endogenous immune milieu. Patients who achieved durable remission beyond five years exhibited a rapid and focused expansion of CAR T cells soon after infusion. More importantly, this therapeutic effect was synergized by a broad and diverse repertoire of the patients’ own CD4+ helper T cells, which remained persistently active and functionally competent over extended periods.

Conversely, patients who relapsed earlier tended to have a higher tumor burden prior to therapy, which correlated with an immunosuppressive state characterized by elevated levels of myeloid-derived suppressor cells (MDSCs). These myeloid populations are known to blunt T cell function through various inhibitory mechanisms, effectively dampening the immune response necessary to sustain remission. The longitudinal data suggest that early myeloid suppression creates a hostile environment for CAR T cell persistence and activity, undermining long-term disease control.

The study underscores the importance of immune system preservation and diversity alongside the engineered CAR T cells. The researchers propose that maintaining a healthy and versatile helper T cell compartment is paramount for sustaining remission, as these cells support cytotoxic responses and coordinate broader immune activity. This insight opens avenues for combinatory therapeutic strategies that not only deliver potent CAR T cells but also modulate the patient’s immune landscape to reduce suppressive elements and promote T cell resilience.

Dr. Alessandro Lagana, the study’s senior author and Assistant Professor of Oncological Sciences at Mount Sinai, emphasized the transformational potential of understanding patient-specific immune dynamics. He notes that these findings could inform more precise selection criteria for CAR T therapy candidates, enable real-time monitoring for relapse through immune biomarkers, and inspire next-generation treatments aimed at fortifying the immune environment.

Mount Sinai’s multidisciplinary team plans to extend their research in larger cohorts to validate these immune signatures. A major goal is to develop a predictive blood test or biomarker panel that could non-invasively forecast which patients are most likely to achieve and maintain long-term remission. Such predictive tools would represent a leap forward in personalized cancer management, guiding therapeutic decisions with unmatched precision.

The implications of this study resonate beyond multiple myeloma, hinting that tailored immunomodulatory approaches could enhance the efficacy and durability of CAR T therapies across various hematologic malignancies. The emphasis on immune system balance and suppression also aligns with emerging paradigms from cancer immunotherapy and tumor microenvironment research.

Funding for this innovative investigation was provided by Mount Sinai’s Center of Excellence for Multiple Myeloma, with collaborative support from pharmaceutical giant Johnson & Johnson—which developed cilta-cel—and Immunai, a company specializing in advanced immune data analytics. Their combined expertise enabled the deployment of cutting-edge technologies that unraveled the complex immune interactions at play.

This landmark study redefines the way clinicians and scientists understand remission maintenance after CAR T cell therapy. It moves the paradigm from viewing CAR T cells purely as a “living drug” to recognizing the integrated ecosystem of immune factors that co-determine therapeutic success. In doing so, it lays the groundwork for future interventions that harness and preserve the full spectrum of the patient’s immune arsenal.

As CAR T cell therapy continues to evolve, the Mount Sinai team’s revelations promise to accelerate the path toward more durable, personalized cancer treatments that not only eradicate tumors but also empower the immune system’s natural capacity to sustain vigilance. The quest to achieve long-lasting cures in multiple myeloma and beyond gains new momentum through this intricate portrait of immune harmony.

Subject of Research: People

Article Title: Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression

News Publication Date: 12-Nov-2025

Web References:
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025018078/548035/Long-term-Remission-After-Cilta-Cel-in-Multiple

References:
Blood Advances, DOI: 10.1182/bloodadvances.2025018078

Keywords: Multiple myeloma, CAR T cell therapy, cilta-cel, immune system, T cell diversity, myeloid suppression, cancer remission

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, combined with hormone therapy, have transformed the therapeutic landscape for advanced HR+/HER2- breast cancer by targeting cell cycle regulatory proteins integral to tumor proliferation. These inhibitors act by halting the cell cycle’s progression from the G1 to the S phase, effectively restraining cancer cell division and tumor growth. Despite the efficacy of this dual treatment approach, resistance and variable patient responses remain significant clinical challenges, underscoring the urgent need for predictive biomarkers.

In a meticulous study involving almost one hundred patients treated at ICO Badalona under the CARE programme, the research team identified a distinctive transcriptomic signature named KIMA (Key Immune Activation). KIMA enables oncologists to forecast a patient’s likelihood of poor response to CDK4/6 inhibitors based on the expression profile of specific immune-related genes. This discovery not only holds potential for predicting therapeutic efficacy but also opens novel avenues for combinatorial treatments incorporating immunomodulation.

The clinical cohort revealed striking differences in treatment outcomes, with 57% of patients achieving durable responses exceeding two years without tumor progression, while 43% experienced early relapse within months. Detailed transcriptomic analyses demonstrated that those patients with adverse outcomes harbored tumors exhibiting aberrant immune activation. This immune signature paradoxically correlates with an immunosuppressive tumor microenvironment, facilitating therapeutic resistance rather than promoting tumor eradication.

KIMA is composed of nine genes, including pivotal immune regulators such as STAT1, FOXP3, and TIGIT. The collective overexpression of these genes in the tumor milieu predicts a significantly diminished prognosis, characterized by accelerated disease progression and poor overall survival. Quantitatively, patients with elevated KIMA expression exhibited a median progression-free survival of approximately 11 months, starkly contrasted with about 36 months in those with low KIMA levels, highlighting its robust prognostic value.

The validity of KIMA was further corroborated through an independent clinical study, which confirmed that non-responders to CDK4/6 inhibitors possess distinct, high-level expression profiles of this immune activation signature. This consistency across datasets underpins KIMA’s potential utility as a clinical decision-making tool, facilitating earlier intervention strategies tailored to the molecular intricacies of each patient’s tumor.

Intriguingly, the study challenges the conventional paradigm that immune activation equates to effective anti-tumor immunity. Instead, in HR+/HER2- breast cancer, hyperactivation of certain immune pathways appears to foster a tumor-supportive environment, possibly through immune checkpoint pathways and regulatory T cell-mediated suppression. This insight sheds light on the complex interplay between tumor biology and the immune system’s dualistic role in cancer progression and therapeutic resistance.

The authors highlight the translational impact of this research, suggesting that patients identified with a high KIMA signature might benefit from novel therapeutic combinations. These could include the addition of innovative immunomodulatory agents aiming to reprogram the tumor microenvironment, thereby restoring immune surveillance and enhancing CDK4/6 inhibitor efficacy. Such personalized approaches promise to optimize treatment regimens and improve patient survival.

Leading the investigation, Dr. Eudald Felip and Dr. Edurne Garcia-Vidal emphasize the importance of integrating immune profiling into routine clinical practice for HR+/HER2- breast cancer. The identification of non-responders through genomic signatures like KIMA could prevent ineffective treatments and unnecessary toxicity while sparing healthcare resources, marking a significant stride in precision oncology.

The research consortium, including Dr. Ester Ballana and Dr. Mireia Margelí, underscores that harnessing the immune system’s intricacies and understanding its regulatory networks within cancerous tissues is pivotal for future therapeutic innovations. This study exemplifies the synergy between molecular biology, oncology, and immunology, providing a template for investigating resistance mechanisms in other cancer types.

Moving forward, large-scale clinical trials incorporating KIMA stratification are planned to validate its predictive power further and assess the efficacy of combined CDK4/6 inhibitor and immunotherapy protocols. Such efforts will be crucial in translating this signature from bench to bedside, ultimately improving survival and quality of life for patients battling HR+/HER2- breast cancer.

The discovery of KIMA and its clinical implications heralds a new chapter in breast cancer treatment, emphasizing the necessity to delve deeper into tumor immunogenomics. Through understanding and overcoming therapeutic resistance, this landmark study brings hope that the era of truly personalized medicine for breast cancer patients is imminent.

Subject of Research: Cells
Article Title: Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
News Publication Date: 7-Aug-2025
Web References: http://dx.doi.org/10.1002/ctm2.70426
Image Credits: ICO-IrsiCaixa-IGTP
Keywords: Breast cancer, Cancer, Oncology, Biomarkers, Immunology

Until now, much of artificial intelligence’s contributions to healthcare have largely been confined to retrospective analyses or theoretical models, leaving a vast potential unfulfilled in direct clinical application. However, led by Professor Dean Ho, Director of the Institute for Digital Medicine (WisDM) at NUS Medicine, the research team has deployed the CURATE.AI platform in a real-world clinical setting—specifically at the National University Cancer Institute, Singapore (NCIS). Their system employed continuous monitoring of two hallmark cancer biomarkers, carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125), across a cohort of 10 patients diagnosed with advanced solid tumors to develop personalized digital twins. These digital twins serve as intimate virtual replicas of individual patients’ tumor biology and therapeutic responses, enabling precise real-time calibration of chemotherapy doses.

By meticulously analyzing the dynamic biomarker fluctuations in response to varying chemotherapy doses, the CURATE.AI platform guided clinicians to adjust treatment regimens with unprecedented precision. Remarkably, over a treatment period spanning from August 2020 to September 2022, 97.2% of the AI-recommended dose modifications were adopted by clinicians. The adjustments led, on average, to approximately 20% lower drug doses in some patients, spotlighting the promising potential to not only maintain therapeutic efficacy but also reduce chemotherapy-induced toxicity and associated healthcare costs.

Traditional oncology often relies on standardized dosing protocols derived from population averages, largely overlooking the considerable heterogeneity in patient responses and tumor evolution during the course of treatment. This limitation presents a pressing challenge as tumor physiology and drug sensitivity are far from static, varying significantly over time within each patient. CURATE.AI circumvents this challenge by harnessing patient-specific, longitudinal clinical data—integrating drug type, administered dose, and objective biomarker responses—to construct an evolving digital pharmacodynamic model. This model empowers the selection of an optimal chemotherapy dose tailored to the patient’s unique, contemporary tumor landscape.

Professor Dean Ho emphasized the innovative nature of this approach, highlighting that many extant AI systems are constrained by reliance on population-level static datasets or retrospective analyses. By contrast, CURATE.AI dynamically responds to individual patient data in real time, effectively capturing intra-patient variability and the continuous metabolic interplay between chemotherapeutic agents and tumor cells. This represents a crucial paradigm shift, enabling iterative, adaptive treatment optimization and heralding the onset of truly precision-guided oncology.

The clinical lead, Associate Professor Raghav Sundar, underscored the translational importance of this study. He reflected on the historical challenge faced by oncologists striving for personalized chemotherapy dosing due to the lack of suitable tools to objectively and dynamically tailor drug regimens. The CURATE.AI trial’s promising findings lay important groundwork for future expansive randomized controlled trials, poised to rigorously evaluate the platform’s efficacy and safety relative to standard-of-care protocols. The clinical implications extend beyond dosing precision, promising to mitigate adverse drug reactions and enhance patient quality of life.

At the core of CURATE.AI’s success lies its sophisticated algorithmic architecture that synergizes Bayesian optimization with mechanistic understanding of cancer biomarker kinetics. Such integration facilitates high-fidelity forecasting of dose-response curves unique to each patient. Furthermore, by repeatedly recalibrating dose selections based on biomarker feedback, the AI system adapts seamlessly to tumor evolution and drug resistance mechanisms that often undermine long-term chemotherapeutic success.

Beyond the study’s immediate oncology focus, the researchers are optimistic about the wider applicability of the CURATE.AI platform across diverse therapeutic domains. Preliminary adaptations are underway to extend its functionalities into immunotherapy regimens, hypertensive medication titration, and interventions designed to enhance healthspan within the longevity medicine landscape. This versatility underscores CURATE.AI’s foundational potential to revolutionize personalized dosing strategies well beyond its initial cancer cohort.

A vital insight from this work, highlighted by co-author Nigel Foo, is the recognition that therapeutic data efficacy is contingent not merely on volume, but on strategic, context-sensitive acquisition. By synchronizing incremental drug dose changes with concomitant biomarker trajectories, CURATE.AI capitalizes on temporal data richness, exposing nuanced pharmacodynamic interactions that are otherwise obscured in traditional clinical datasets. The concept of digital twins crystallizes this insight, enabling a feedback loop of data-driven, patient-specific care planning.

This research represents one of the first tangible illustrations of an AI-driven platform being integrated into everyday clinical treatment decisions, moving beyond the laboratory or theoretical sphere into the practical domain where patients benefit directly. The feasibility trial lays a robust foundation for subsequent multi-center trials with larger sample sizes designed to scrutinize the platform’s reproducibility and impact on long-term clinical outcomes such as progression-free survival and overall survival.

Published recently in the distinguished journal npj Precision Oncology, the findings position CURATE.AI at the frontier of next-generation oncology therapeutics. While conventional cancer care largely depends on pre-defined dosing schemas resistant to mid-course alterations, CURATE.AI epitomizes an adaptive, continuously learning system. Such agility aligns with the emerging understanding of cancer as a highly heterogeneous and time-variant disease, necessitating equally dynamic treatment strategies.

Ultimately, the success of this AI-enabled personalized dosing platform holds profound implications for healthcare economics. By potentially lowering drug dosages without compromising efficacy, CURATE.AI could alleviate the financial burden on healthcare systems and patients alike while limiting exposure-related toxicities that diminish patients’ quality of life. This dual advantage represents a compelling incentive for accelerating regulatory approval processes and clinical adoption worldwide.

As the oncology community grapples with escalating complexity in cancer management and burgeoning molecular data streams, CURATE.AI exemplifies the transformative convergence of digital health technologies with precision medicine. Its ability to deliver individualized, evidence-based treatment adjustments in real time crystallizes the promise of AI not merely as an analytical tool, but as a direct driver of improved patient outcomes in routine clinical care.

Subject of Research: Personalized dose selection platform for patients with advanced solid tumors using AI-driven digital twins.

Article Title: Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial.

News Publication Date: 21-Feb-2025

Web References:
https://www.nature.com/articles/s41698-025-00835-7
http://dx.doi.org/10.1038/s41698-025-00835-7

Image Credits: NUS Medicine

Keywords: Cancer research, Digital data, Drug therapy, Artificial intelligence, Cancer patients, Cancer medication, Chemotherapy, Drug studies, Chemical analysis